Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-10
2007-04-10
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S184000, C546S192000, C546S208000, C546S210000, C514S315000, C514S317000
Reexamination Certificate
active
10714066
ABSTRACT:
4-Tetrazolyl-4-phenylpiperidine Compounds, compositions comprising an effective amount of a 4-Tetrazolyl-4-phenylpiperidine Compound, methods for treating or preventing pain or diarrhea in an animal comprising administering to an animal in need thereof an effective amount of a 4-Tetrazolyl-4-phenylpiperidine Compound and methods for stimulating opioid-receptor function in a cell comprising contacting a cell capable of expressing an opioid receptor with an effective amount of a 4-Tetrazolyl-4-phenylpiperidine Compound are disclosed.
REFERENCES:
patent: 5606037 (1997-02-01), Attardo et al.
patent: 5736523 (1998-04-01), Attardo et al.
patent: 5849737 (1998-12-01), Chaplan et al.
patent: 5849761 (1998-12-01), Yaksh
patent: 5994372 (1999-11-01), Yaksh
patent: 6166039 (2000-12-01), Yaksh
patent: 6166085 (2000-12-01), Chaplan et al.
patent: 6221888 (2001-04-01), Durette et al.
patent: 6358945 (2002-03-01), Breitfelder et al.
patent: 6362203 (2002-03-01), Mogi et al.
patent: 6423519 (2002-07-01), Bergnes et al.
patent: 6486142 (2002-11-01), Leblanc et al.
patent: 6544981 (2003-04-01), Stein et al.
patent: 6573282 (2003-06-01), Yaksh et al.
patent: 6576650 (2003-06-01), Yaksh
patent: 6586430 (2003-07-01), Armour et al.
patent: 6608052 (2003-08-01), Breitfelder et al.
patent: 6703525 (2004-03-01), Kapadia et al.
patent: 6790854 (2004-09-01), Tsushima et al.
patent: 1097924 (2001-05-01), None
patent: 1219294 (2002-07-01), None
patent: 1277737 (2003-01-01), None
patent: 1325912 (2003-07-01), None
patent: 949560 (1974-06-01), None
patent: WO 97/24325 (1997-07-01), None
patent: WO 99/45011 (1999-09-01), None
patent: WO 00/39125 (2000-07-01), None
patent: WO 01/39775 (2001-06-01), None
patent: WO 02/38185 (2002-05-01), None
Ankier, “New hot plate tests to quantify antinociceptive and narcotic antagonist activities”, Eur. J. Pharmacol. 27:1-4 (1974).
Bernton et al., “Release of multiple hormones by a direct action of interleukin-1 on pituitary cells”, Science 238:519-521 (1987).
Bristow et al., “L-745,870, a subtype selective dopamine D4receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests”, J. Pharmacol. Exp. Ther. 283:1256-1263 (1997).
Chen et al., “Molecular cloning and functional expression of a μ-opioid receptor from rat brain” Mol. Pharmacol. 44:8-12 (1993).
Cheng and Prusoff, “Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction”, Biochem. Pharmacol. 22:3099-3108 (1973).
Childers, “Opiate-inhibited adenylate cyclase in rat brain membranes depleted of Gs-stimulated adenylate cyclase”, J. Neurochem. 50:543-553 (1988).
D'Amour and Smith, “A method for determining loss of pain sensation”, J. Pharmacol. Exp. Ther. 72:74-79 (1941).
Duggan and North, “Electrophysiology of opioids”, Pharmacol. Rev. 35:219-281 (1983).
Evans et al., “Cloning of a delta opioid receptor by functional expression”, Science 258(5090):1952-1955 (1992).
Ficker et al., “Molecule determinants of dofetilide block of HERG K+ channels”, Circ. Res. 82:386-395 (1998).
Fields and Basbaum, in:Textbook of Pain, Wall and Melzack, eds., Churchill Livingstone, Edinburgh pp. 309-343, (1999).
Green, “Comparative effects of analgesics on pain threshold, respiratory frequency and gastrointestinal propulsion”, Br. J. Pharmacol. 14:26-34 (1959).
Grupp et al., “Protection against hypoxia-reoxygenation in the absence of poly (ADP-ribose) synthetase in isolated working hearts”, J. Mol. Cell Cardiol. 31:297-303 (1999).
Hamill et al., “Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches”, Pflugers Arch. 391:85-100 (1981).
Harrison et al., “Conversion of carboxamides and oximes to nitriles or imidoyl chlorides using a polymer-supported phosphine and carbon tetrachloride” Synthesis, pp. 41-43 (1997).
Hassan et al., “Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue”, Neuroscience 55(1):185-195 (1993).
Heddle et al., “Micronuclei as an index of cytogenetic damage: past, present, and future”, Environ. Mol. Mutagen. 18:277-291 (1991).
Ingram and Williams, “Opioid inhibition of Ihvia adenylyl cyclase”, Neuron 13:179-186 (1994).
Jenkins et al., “Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands”, J. Med. Chem. 35:2392-2406 (1992).
Ji et al.;, “Expression of μ-, δ-, and κ-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation”, J. Neurosci. 15:8156-8166 (1995).
Kieffer et al., “The δ-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization”, Proc. Natl. Acad. Sci. USA 89:12048-12052 (1992). Erratum in: Proc. Natl. Acad. Sci. USA 91:1193 (1994).
Kieffer and Gaveriaux-Ruff, “Exploring the opioid system by gene knockout”, Prog. Neurobiol. 66:285-306 (2002).
Kiehn et al., “Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide”, Circulation 94:2572-2579 (1996).
Kong et al., “Agonists and antagonists bind to different domains of the cloned κ opioid receptor”, Proc. Natl. Acad. Sci. USA 91:8042-8046 (1994).
LeCluyse, “Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation”, Eur. J. Pharm. Sci. 13:343-368 (2001).
Maron and Ames, “Revised methods for theSalmonellamutagenicity test”, Mutat. Res. 113:173-215 (1983).
Meng et al., “Cloning and pharmacological characterization of a rat κ opioid receptor”, Proc. Natl. Acad. Sci. USA 90:9954-9958 (1993).
Minami et al., “Cloning and expression of a cDNA for the rat κ -opioid receptor” , FEBS Lett. 329(3):291-295 (1993).
Mohammad et al., “Blockage of the HERG human cardiac K+channel by the gastrointestinal prokinetic agent cisapride”, Am. J. Physiol. 273(5 Pt 2):H2534-H2538 (1997).
Moser et al., “Comparison of chlordimeform and carbaryl using a functional observational battery”, Fundam. Appl. Toxicol. 11:189-206 (1988).
Mousa et al., “Local upregulation of corticotropin-releasing hormone and interleukin-1 receptors in rats with painful hindlimb inflammation”, Eur. J. Pharmacol. 311:221-231 (1996).
Ohmura et al., “Effects of terfenadine, astemizole and epinastine on electrocardiogram in conscious cynomolgus monkeys”, Eur. J. Pharmacol. 378:169-175 (1999).
Randall and Selitto, “A method for measurement of analgesic activity on inflamed tissue”, Arch. Int. Pharmacodynam. 3:409-419 (1957).
Rasenick and Childers, “Modification of Gs-stimulated adenylate cyclase in brain membranes by low pH pretreatment: correlation with altered guanine nucleotide exchange”, J. Neurochem. 53:219-25 (1989).
Sato et al., “New μ-opioid receptor agonists with phenoxyacetic acid moiety”, Chem. Pharm. Bull. 50:292-297 (2002).
Selley et al., “Modification of G protein-coupled functions by low-pH pretreatment of membranes from NG108-15 cells: increase in opioid agonist efficacy by decreased inactivation of G proteins”, Mol. Pharmacol. 44:731-741 (1993).
Sharp and Linner, “What do we know about the expression of proopiomelanocortin transcripts and related peptides in lymphoid tissue?”, Endocrinology 133:1921A-1921B (1993).
Stein et al., “Unilateral inflammation of the hindpaw in rats as a model of prolonged noxious stimulation: alterations in behavior and nociceptive thresholds”, Pharmacol. Biochem. Behav. 31:445-451 (1988).
Stein et al., “Opioids from immunocytes intera
Euro-Celtique S.A.
Jones Day
Shameem Golam M. M.
LandOfFree
Therapeutic agents useful for treating pain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agents useful for treating pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents useful for treating pain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3746365